Loading
Verdinexor (Laverdia) is a tablet for dogs with lymphoma, the first oral lymphoma treatment for dogs to gain full approval from the US Food and Drug Administration. It works the same way as the human myeloma drug selinexor.
Laverdia (verdinexor tablets) was conditionally approved by the FDA Center for Veterinary Medicine in January 2021 through the Minor Use/Minor Species pathway and, after four annual renewals, received full approval under NADA 141-614 (Freedom of Information Summary dated 18 December 2025; FDA update of 16 January 2026), sponsored by Anivive Lifesciences, Inc., of Long Beach, California, for the treatment of lymphoma in dogs. The starting dose is 1.25 mg/kg by mouth twice a week, at least 72 hours apart, given with food.
In the field study of dogs with naive or relapsed B-cell or T-cell lymphoma (106 treated, 28 controls), median time to progression was 37 days (95% CI 29 to 57) with verdinexor against 23 days (14 to 30) in controls (P = 0.011). Verdinexor was studied as KPT-335 and blocks the same exporter, XPO1, as the human drug selinexor. It is a veterinary medicine and has no human approval.
A selective inhibitor of nuclear export that blocks chromosome region maintenance 1 (exportin 1, XPO1), keeping tumour suppressor and growth regulatory proteins in the nucleus where they control cell growth; the same mechanism as the human drug selinexor. Connects to Exportin-1 (XPO1).
1.Cancer cells pump growth-controlling proteins out of the nucleus through the exporter XPO1
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Verdinexor" OR ABSTRACT:"Verdinexor" OR TITLE:"Laverdia" OR ABSTRACT:"Laverdia" OR TITLE:"KPT-335" OR ABSTRACT:"KPT-335" OR TITLE:"verdinexor tablets" OR ABSTRACT:"verdinexor tablets") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Verdinexor, not a curated reading list.
Shares Veterinary and comparative oncology, Pet dogs with spontaneous cancer as a bridge before human trials and the tags veterinary, comparative-oncology.
Shares Veterinary and comparative oncology, Pet dogs with spontaneous cancer as a bridge before human trials and the tags veterinary, comparative-oncology.
Shares Veterinary and comparative oncology, Pet dogs with spontaneous cancer as a bridge before human trials and the tags veterinary, comparative-oncology.
Shares Veterinary and comparative oncology, Pet dogs with spontaneous cancer as a bridge before human trials and the tags veterinary, comparative-oncology.
Shares the tags veterinary, comparative-oncology.
Shares the tags veterinary, comparative-oncology.
Shares the tags veterinary, comparative-oncology.
Shares Exportin-1 (XPO1), Selinexor.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/